Himabindu Ramachandrareddy

Himabindu Ramachandrareddy has a diverse work experience that spans over various roles and industries. Himabindu started their career as a Veterinary Surgeon at the Veterinary Polyclinic in 2004. From 2005 to 2012, they worked as a Graduate Research Assistant at the University of Nebraska Medical Center, where they focused on analyzing epigenetic regulation of B cell specific transcription factors. During their time there, they also conducted research on Hodgkin lymphoma and identified a novel regulatory element.

In 2012, Himabindu joined Harvard Medical School as a Post-doctoral Fellow, and they continued their research on diffuse large B cell lymphomas (DLBCL) and drug resistant mechanisms. Himabindu contributed to deriving therapeutic combination regimens and exploring metabolic plasticity and vulnerabilities in DLBCL subtypes. Himabindu gained experience with small molecule chemical inhibitors and testing their efficacy in vitro disease models.

Following their time at Harvard, Himabindu moved to the Dana-Farber Cancer Institute, where they continued their post-doctoral fellowship. Here, they focused on analyzing drug resistant mechanisms in DLBCL and worked on developing treatment strategies. Himabindu also gained experience in working with small molecule chemical inhibitors and testing their efficacy in vitro disease models.

In 2015, Himabindu joined 1Globe Health Institute as a Postdoctoral Research Fellow in Immuno Oncology. Himabindu led pre-clinical work in the design and development of bi-specific antibody proteins for activating immune effector T lymphocytes and targeting tumor cells. Himabindu'swork involved molecular design and cloning of bi-specific antibodies, protein purification and characterization, as well as testing the efficacy of these antibodies in vitro and in vivo disease models.

From 2019 to 2022, Himabindu worked at Siemens Healthineers as a Biochemist II/Scientist IVD Immuno Assays. In this role, they served as the lead biochemist in characterization, verification, and validation activities for process and product improvement in a GMP environment. Himabindu authored plans, reports, and protocols, and was responsible for analytical investigations and troubleshooting of nonconformances during QC testing.

Most recently in 2022, Himabindu joined Voyager Therapeutics, Inc. as a Senior Scientist I. Himabindu'sspecific responsibilities in this role are not provided, but it can be inferred that they are continuing their scientific work in a senior capacity.

Overall, Himabindu Ramachandrareddy has a strong background in scientific research with a focus on cancer biology and drug development. Himabindu has experience in leading projects, conducting experiments, and analyzing data in both academic and industry settings.

Himabindu Ramachandrareddy holds a Ph.D. degree in Molecular Biology with a specialization in lymphoma from the University of Nebraska Medical Center, which was completed in 2012. Prior to this, in 2004, they obtained an Advanced Diploma in Bioinformatics at the Indian Institute of Chemical Technology. From 2001 to 2003, Himabindu pursued an M.V.Sc degree in Veterinary Biochemistry at Acharya N.G.Ranga Agricultural University. Before that, they completed their D.V.M degree in Veterinary Medicine at the same university, between 1996 and 2001.